University of Exeter Medical School

Catherine Angwin

Catherine Angwin

Diabetes Research Project Manager & PhD Student

 C.Angwin@exeter.ac.uk

 01392 408185

 RILD Building 

 

University of Exeter Medical School, RILD Building, RD&E Hospital Wonford, Barrack Road, Exeter, EX2 5DW, UK

Overview

Catherine has been part of the diabetes research team, led by Prof Andrew Hattersley since 2010, working on clinical research projects in diabetes, including genetics of diabetes and most recently stratification of Type 2.

She is currently manages the TriMaster clinical trial, a randomised double-blind three-way crossover trial of third-line diabetes therapies which aims to improve diabetes care by identifying groups of patients who may respond better to certain diabetes treatments. She is also involved in the NIHR Global Health project working to improve diabetes diagnosis and treatment in sub-Saharan Africa in collaboration with partners in Uganda and Cameroon. 

Alongside these role she is a part-time PGR student looking at stratified medicine and treatment hetergeneity in Type 2 Diabetes. 

Catherine is based in the NIHR Exeter Clinical Research Facility and UEMS Medical School.  Previous studies include the MASTERMIND and RetroMASTER clinical studies, work with the Stroke Research Network for the INTERSTROKE study and the EU IMI-DIRECT and FP7-CEED3 projects.

Qualifications

MSc International Development (University of Bristol) 

Research group links

Back to top

Research

Research interests

Catherine's work is largely in clinical trials and research projects linked to stratification of Type 2 diabetes.

Research projects

  • MRC-ABPI Stratification and Extreme Response Mechanism IN Diabetes (MASTERMIND), including MASTERMIND and RetroMASTER clinical studies
  • NIHR Global Health: Improving outcomes in sub-Saharan African diabetes through better diagnosis and treatment 
  • Diabetes Research on Patient Stratification (DIRECT)

Previous projects: 

  • INTERSTROKE study - A study of the Importance of Conventional and Emerging Risk Factors of Stroke
  • Collaborative European Effort to Develop Diabetes Diagnostics (CEED3)

Back to top

Publications

Journal articles

Dennis J, Henley W, Weedon M, Lonergan M, Rodgers L, Jones A, Hamilton W, Sattar N, Janmohamed S, Holman R, et al (In Press). Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and individual trial data. Diabetes Care
McGovern A, Shields B, Hattersley A, Pearson E, Jones AG (In Press). What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? a MASTERMIND study. BMC Medicine
Shields BM, Angwin CD, Shepherd MH, Britten N, Jones AG, Sattar N, Holman R, Pearson ER, Hattersley AT (2022). Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study. Nature Medicine, 29(2), 384-391.
Shields BM, Dennis JM, Angwin CD, Warren F, Henley WE, Farmer AJ, Sattar N, Holman RR, Jones AG, Pearson ER, et al (2022). Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study. Nature Medicine, 29(2), 376-383.
McGovern AP, Hogg M, Shields BM, Sattar NA, Holman RR, Pearson ER, Hattersley AT, Jones AG, Dennis JM (2020). Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Research & Care, 8(1), e001238-e001238. Abstract.
Angwin C, Jenkinson C, Jones A, Jennison C, Henley W, Farmer A, Sattar N, Holman RR, Pearson E, Shields B, et al (2020). TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol. BMJ Open, 10(12), e042784-e042784. Abstract.
Angwin C, Pearson E, Hattersley A (2016). Crossover studies can help the individualisation of care in type 2 diabetes: the MASTERMIND approach. Practical Diabetes, 33(4), 115-117.

Conferences

Shields B, Angwin C, Jones AG, Holman RR, Sattar N, Britten N, Pearson E, Shepherd M, Hattersley AT (2022). Let the patient choose! Patient preferences for type 2 diabetes therapy in the trimaster double-blind three-way randomised crossover trial.  Author URL.
Angwin CD, Shields BM, Jones AG, Pearson ER, Hattersley AT (2022). Raised levels of brain natriuretic peptide (BNP) in patients with type 2 diabetes but no known heart failure are rare and not associated with improved response to SGLT2 inhibitors: Findings from the TriMaster study.  Author URL.
Rickards NF, Angwin C, Pearson ER, Hattersley AT (2019). Patients choose glucose lowering Type 2 diabetes therapy based on their own tolerability experience rather than glycaemia or weight considerations: Evidence from the blinded TriMaster study.  Author URL.
Grubb AL, Patel K, Oram RA, Hill AV, Angwin C, McDonald TJ, Weedon MN, Hattersley AT, Owen KR, Shields BM, et al (2018). Development and validation of a clinical prediction model to identify adult patients (aged 18-50) with type 1 diabetes requiring early insulin therapy.  Author URL.
Shakweh EY, Shields BM, Angwin CD, Rodgers LR, McDonald TJ, Pearson ER, Hattersley AT, Jones AG (2018). Precision medicine in Type 2 diabetes: is variation in response to sitagliptin and gliclazide therapy related to drug levels?.  Author URL.
Grubb AL, Patel KA, Oram RA, Hill AV, Angwin C, McDonald TJ, Weedon MN, Hattersley AT, Shields BV, Jones AG, et al (2017). Development of a risk calculator to identify patients with Type 1 diabetes who will require early insulin therapy.  Author URL.
Jones AG, Angwin C, Hammersley S, Rogers L, Shields BM, Pearson ER, Hattersley AT (2016). The DPPIV inhibitor sitagliptin lowers postprandial glucose without improving postprandial insulin secretion: a MASTERMIND study.  Author URL.
Dennis JM, Hattersley AT, Weedon M, Angwin C, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Development of oedema is associated with an improved glycaemic response in patients initiating thiazolidinediones: a MASTERMIND study.  Author URL.
Dennis JM, Hattersley AT, Weedon M, Angwin CD, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Patients who develop oedema on initiating thiazolidinedione therapy have an improved glycaemic response: a MASTERMIND study.  Author URL.
Rodgers LR, Pearson ER, Hammersley S, Angwin CD, JMcDonald T, Shields BM, Hattersley AT, Jones AG (2015). Patients with a high fasting glucose respond better to sulphonylureas than dipeptidyl peptidase IV (DPP-IV) inhibitors: a MASTERMIND study.  Author URL.
Rodgers LR, Pearson ER, Angwin CD, Hammersley S, McDonald TJ, Shields BM, Hattersley AT, Jones AG (2015). Response to glucose lowering therapy can be assessed by a brief period of treatment withdrawal: a MASTERMIND study.  Author URL.

Back to top

Edit Profile